Resistance to anthracyclines is related to a poor prognosis in childhood acute lymphoblastic leukemia (ALL). Resistance to this class of drugs may (partly) be reversed by modulating agents, as has been demonstrated in a variety of cell lines. However, it is unknown which modulators may be of clinical benefit in childhood ALL. Therefore, we studied the modulating effect of PSC 833, cyclosporin A (CsA), verapamil (Vp) and genistein on daunorubicin (DNR) cytotoxicity, accumulation and retention in childhood ALL cells. DNR cytotoxicity was determined using the MTT assay; DNR accumulation, DNR retention and the expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and major vault protein/lung resistance protein (LRP) were determined by flow cytometry. In the majority of samples PSC 833 (19/26), CsA (22/26) and Vp (15/18) sensitized the cells to DNR whereas genistein made 25 out of 26 samples more resistant to DNR. The sensitizing effect on the cytotoxicity of DNR was median 1.2-fold using 2 M PSC 833 (P = 0.025), 1.5-fold using 4 M CsA (P = 0.003) and 1.6-fold using 6 M Vp (P = 0.012) whereas the adverse effect of 25 M genistein was median 1.8-fold (P Ͻ 0.0001). No relationship was found between the sensitizing effect of PSC 833, CsA or Vp and the degree of DNR resistance. In contrast, the adverse effect of genistein was largest in DNR sensitive samples (P = 0.003). The effect of each modulator on the cytotoxicity of DNR did not differ between initial and relapse ALL samples although the latter were median 1.4-fold more resistant to DNR (P = 0.005). Modulation of DNR cytotoxicity was not correlated with changes in the accumulated and retained intracellular DNR content or with the expression of Pgp, MRP and LRP. Besides genistein, PSC 833, CsA and Vp incidentally made ALL cells more resistant to DNR. CsA stimulated the leukemic cell survival in seven out of 26 samples, a phenomenon that was not related to the degree of DNR resistance. In conclusion, PSC 833, CsA and Vp but not genistein may be used to sensitize cells to DNR in childhood ALL. The data also indicate that not all patients may have a therapeutic benefit from these modulators. Therefore, an in vitro culture assay may be necessary to screen for patients who may benefit by a modulator in their therapy.
Introduction
Resistance to combination chemotherapy or recurrence of the disease is still a problem in about 30% of children with acute lymphoblastic leukemia (ALL). The risk of treatment failure is related to cellular resistance to different classes of drugs such as anthracyclines, glucocorticoids, L-asparaginase and vinca alkaloids. [1] [2] [3] Strategies to circumvent drug resistance include the development of new drugs and modulators of resistance. In childhood ALL, cross-resistance to anthracyclines is often Correspondence observed, including new drugs such as idarubicin and aclarubicin. 4 Therefore, modulation of the cellular response to anthracyclines may be a valulable approach in overcoming anthracycline resistance in childhood ALL.
The number of resistance modulating agents is increasing, and includes calcium channel blockers, calmodulin inhibitors, cyclosporins, steroids, protein kinase inhibitors, antibiotics and antimalaria agents. The mechanisms of modulation are probably multifactorial just as the mechanisms of drug resistance are. In a variety of cell lines and clinical samples, modulators such as the calcium channel blocker verapamil (Vp) and cyclosporin A (CsA) have been shown to inhibit the efflux of drugs out of cells resulting in an increase of intracellular drug levels. These modulators have been demonstrated to interact with drug efflux-mediating proteins present in the plasma membrane, ie P-glycoprotein (P-gp) and the multidrug resistance-associated protein (MRP). 5, 6 These proteins transport drugs belonging to the anthracyclines, vinca alkaloids and epipodophyllotoxins. Cells expressing P-gp or MRP are therefore often cross-resistant to these classes of drugs, a phenomenon called multidrug resistance (MDR). Besides P-gp and MRP the major vault protein/lung resistance protein (LRP) has also been associated with drug resistance and lower intracellular drug levels. 7, 8 The first modulators described, Vp and CsA, were initially thought to specifically inhibit P-gp-mediated MDR. Presently, these modulators were also demonstrated to modulate MRPmediated drug resistance. 9, 10 A more specific MRP/LRP modulator may be genistein, an isoflavone with protein tyrosine kinase inhibitory activity. Genistein has been found to increase the accumulation and retention of the anthracycline daunorubicin (DNR) in non-P-gp but not in P-gp expressing cell lines. 11 However, the modulating effect of genistein was only observed at a high concentration, which was lethal to the cells in a 5-day culture assay. A less cytotoxic modulator of MDR may be PSC 833, a new cyclosporin analogue. In cell line studies this modulator was at least 10-fold more potent in reversing drug resistance compared with CsA.
12 Both P-gpand non-P-gp-mediated MDR may be affected by PSC 833, although the effect on the latter may be less pronounced. 9 In the present study we determined the modulating effect of PSC 833, CsA, Vp and genistein on the cytotoxicity of DNR in childhood ALL. The nature of the modulating effect was studied by analyzing the effect on the accumulation and retention of DNR and the expression of P-gp, MRP and LRP in these samples.
Materials and methods

Leukemic cell samples
Bone marrow and peripheral blood samples from 46 children at initial diagnosis and 19 unrelated children at relapse of ALL 913 were sent by hospitals participating in the German COALL study group and ALL-REZ BFM group, respectively. In maximal 26 samples the effect of four modulators on the in vitro DNR cytotoxicity, DNR accumulation/retention and expression of resistance proteins was studied. In 18 other samples the effect of a lower genistein concentration (5 M) on DNR cytotoxicity was measured. Additionally, DNR accumulation and retention with and without PSC 833 and expression of resistance proteins was measured in 21 samples without studying the PSC 833 effect on DNR cytotoxicity in these samples.
Within 24 h of sampling, mononuclear cells were separated using Lymphoprep (density 1.077 g/ml; Nycomed Pharma, Oslo, Norway), washed and resuspended in RPMI 1640 (Dutch modification; Gibco BRL, Breda, The Netherlands) containing 20% fetal calf serum (FCS; Gibco BRL), 2 mM lglutamine (ICN, Costa Mesa, CA, USA), 5 g/ml insulin, 5 g/ml transferrin, 5 ng/ml sodium selenite (Sigma, St Louis, MO, USA) and antibiotics. Contaminating normal cells were eliminated using monoclonal antibodies linked to magnetic beads as previously described. 13 All processed samples contained more than 80% leukemic cells which was determined on cytospin preparations stained with May-Grü nwald Giemsa (MGG; Merck, Darmstadt, Germany). The viability of cells was determined by trypan blue exclusion, and was Ͼ90% at the start of all experiments.
Daunorubicin and modulators
Daunorubicin-HCl (DNR; Cerubidin) was obtained from Rhô ne Poulenc Rorer, Amstelveen, The Netherlands. SDZ PSC 833 was obtained from Sandoz, Uden, The Netherlands. Purified cyclosporin A (CsA) was a gift from Dr SW Klein, pharmacy, University Hospital Utrecht, The Netherlands. Racemic verapamil (Vp) and genistein were from Sigma. Stock solutions were prepared of PSC 833 (5 mM), CsA (5 mM) and genistein (20 mM) in absolute ethanol and of Vp (20 mM) and DNR (5 mg/ml) in distilled water. All stock solutions were stored at −20°C. The final concentration of ethanol in RPMI 1640 medium was maximal 0.2%, which did not affect the accumulation, retention and cytotoxicity of DNR.
In vitro drug resistance assay
The MTT assay was used to determine the effect of modulators on the cytotoxicity of DNR. The assay conditions have been well-characterized and standardized as previously described. [13] [14] [15] In 96-well round-bottomed microculture plates (Greiner Labortechnik, Alphen aan den Rÿn, The Netherlands), leukemic cells (160 000 cells/well) were incubated with six different concentrations of DNR ranging from 0.002 to 2 g/ml with and without the indicated concentration of modulator in humidified air containing 5% CO 2 . Control leukemic cells from the sample were incubated with and without the modulator only. After 4 days of culture at 37°C, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT; Sigma) was added to each well (0.45 mg/ml final concentration), which can be reduced into formazan by viable cells only. After incubation for 6 h at 37°C, the formazan crystals were dissolved using 0.04 M HCl in isopropanol. The quantity of reduced product was measured spectrophotometrically at 562 nm (Bio-Kinetics Reader; Bio-Tek Instruments, Winooski, VT, USA). The optical density (OD) value at 562 nm is linearly related to the number of viable leukemic cells.
14 Samples with more than 70% of leukemic cells in the control wells after 4 days of culture (without drug) and a control OD value higher than 0.050 arbitrary units (adjusted for blank values) were used to calculate the LC 50 value, ie the concentration of drug that is lethal to 50% of the cells (in g/ml). 13, 16 The LC 50 of DNR in the presence of the modulator was corrected for the cell kill mediated by the modulator itself. The modulating effect on DNR cytotoxicity was expressed as the ratio between the LC 50 value of DNR with and without modulator: a ratio Ͼ1 indicates a sensitizing effect of the modulator, ie the LC 50 of single DNR was higher than the LC 50 of DNR in the presence of the modulator; a ratio Ͻ−1 indicates an adverse effect of the modulator, ie the LC 50 of DNR in the presence of the modulator is higher than the LC 50 of single DNR.
DNR accumulation and retention
Cells at a concentration of 0.5 × 10 6 /ml were preincubated in the presence or absence of the modulator for 30 min at 37°C. Next, cells were incubated with 10 g/ml DNR with or without the modulator at 37°C. The accumulated DNR content was determined after 60 and 300 min of incubation, ie when, under the present conditions, cells have accumulated half of the maximum (t = 60 min) and the maximum intracellular DNR content (t = 300 min). 17 To study the retention, cells were incubated with DNR with or without modulator for 60 min at 37°C, washed at 4°C and resuspended in a prewarmed DNR-free medium with or without modulator, respectively. After 60 min and 300 min of efflux, aliquots were taken to determine the retained DNR content. At these timepoints, half of the intracellular accumulated DNR has effluxed out of the cell (t = 60 min) or a steady state in the retained DNR content has been reached (t = 300 min). 17 The intracellular DNR content was measured by flow cytometry (FACScan; Becton Dickinson, Erembodegem, Belgium) using standardized instrument settings as described elsewhere. 17 The fluorescence signal was collected through a 585/42 bandpass filter set, the signal was further processed using log mode amplification (FL-2 height). The data were analyzed using LYSYS II software (Becton Dickinson). Leukemic cells were gated based on forward and sideward scatter characteristics. The mean fluorescence intensity of the gated cells was used as a measure for the intracellular DNR content, which was expressed in arbitrary units (AU) on a log-scale. All measurements were normalized using propidium iodide-labeled reference beads (PI-beads; Flow Cytometry Standards Corporation, San Juan, PR, USA). The effect of the modulator on the accumulated and retained DNR content in cells was defined as the percentage of change in the intracellular DNR content in the presence of the modulator compared with the intracellular DNR content measured in the absence of the modulator.
The human epidermoid carcinoma KB3-1 cell line (parental) and the five-fold DNR resistant and P-gp positive KB8-5 subline were used to validate the applied method for studying the modulation of DNR accumulation and retention. 11, 18 Expression of drug resistance proteins Expression of drug resistance proteins was measured using an optimized method for childhood ALL cells as recently described. 19 The expression of P-gp was detected by MRK16 (mouse IgG2a, 5 g/ml; Kamiya Biomedical Company, Thousand Oaks CA, USA). MRP was detected by MRPr1 (rat IgG2a, 1.7 g/ml) and LRP by LRP56 (mouse IgG2b, 0.6 g/ml). 7, 20 Non-specific isotype-matched antibodies (Dako, Glostrup, Denmark) were used at the same IgG concentrations as the specific antibodies. Cells were fixed for 10 s at room temperature using 2% (v/v) 37% formaldehyde solution in acetone. Cells were incubated with the primary antibody for 45 min at room temperature, washed and incubated with fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse F(ab′) 2 or anti-rat antibodies (1:50 and 1:500, respectively; Dako) for 30 min at room temperature. FITC-labeling was detected by flow cytometry (FACScan; Becton Dickinson) using a 530/30 nm bandpass filter set and a logarithmic amplification of the signal. The data were analyzed using LYSYS II software (Becton Dickinson). Leukemic cells were gated based on forward and sideward scatter characteristics and the fluorescence intensity of the gated population was expressed in arbitrary units on a log-scale. The fluorescence index (FI) was used as measure for the intensity of staining and represents the ratio between the mean fluorescence intensity of cells stained with the specific antibody and that of cells stained with the isotypematched control antibody.
Statistical methods
The Wilcoxon signed rank test and Mann-Whitney U test were used for analysis of respectively paired and unpaired observations. The relationship between two variables was tested by the Spearman rank correlation test (R s ). A P value smaller than 5% was considered to be statistically significant (two-tailed tested).
Results
Toxicity of modulators
The modulators were tested at a concentration which resulted in less than 15% cell kill by the modulator only; ie 2 M PSC 833, 4 M CsA, 6 M Vp and 25 M genistein. The median leukemic cell survival after 4 days of culture in the presence of the modulator compared with control cells cultured without modulator was PSC 833 99%, CsA 101%, Vp 93% and genistein 85%. Remarkably, in seven out of 26 childhood ALL samples the control cell survival in the presence of CsA was higher than 110% (with a maximum of 164%) compared with cells cultured in the absence of the modulator (100% by definition). Samples with and without increased cell survival in the presence of CsA did not differ in the in vitro response to DNR (P Ͼ 0.05). No increase in cell survival was observed in samples cultured with PSC 833, Vp or genistein. The OD expressed per cell did not significantly differ between cells cultured with and without each of the modulators.
Modulating effect on in vitro DNR cytotoxicity
The effect of PSC 833, CsA, Vp and genistein on the in vitro cytotoxicity of DNR in childhood ALL cells is shown in The modulating effect of PSC 833, CsA and Vp was not related to the degree of DNR resistance. In contrast, the most DNR-sensitive patients became more resistant in the presence of genistein compared with the most resistant patients (Figure 1d ; R s 0.58, P = 0.003). The same result was obtained when a less cytotoxic concentration of 5 M genistein was tested (median cell survival after 4 days of culture 97%; R s 0.64, P = 0.004, n = 18). Figure 2 shows a representative example of the effect of modulators on the cytotoxicity of DNR in initial and relapse ALL. The modulating effect did not differ between initial and relapse samples, although the relapse samples were median 1.4-fold more resistant to DNR (median LC 50 DNR 0.08 and 0.11 g/ml for initital and relapse ALL, respectively; P = 0.005). The effect of PSC 833, CsA, Vp or genistein on the cytotoxicity of DNR was not related to the expression of the drug resistance proteins P-gp, MRP and LRP (R s : P Ͼ 0.05 for each combination of modulator and drug resistance protein).
Modulating effect on DNR accumulation and retention
The parental P-gp-negative KB3-1 cell line (FI MRK16/IgG2a = 1.0) and the DNR-resistant and P-gp-expressing subline KB8-5 (FI MRK16/IgG2a = 3.4) were used to validate the applied method for studying the modulation of DNR accumulation and retention. The concentrations of modulators that were used in the present study, ie 2 M PSC 833, 4 M CsA and 6 M Vp reversed the accumulation deficits of KB8-5 cells by respectively 1.9-fold, 1.5-fold and 1.7-fold and the retention deficits by respectively 2.3-fold, 1.7-fold and 2-fold compared with the intracellular DNR content measured in the absence of modulator (60 min time-point). The effect of these modulators on the intracellular DNR content of KB3-1 cells was only limited (less than 10% change). The non-P-gp modulator genistein (25 M) did not enhance the accumulation and retention of DNR in KB3-1 and KB8-5 cells. These data confirm earlier reports by others and validate the presently applied method. 11, 18 The effects of the modulators on the accumulation and retention of DNR in childhood ALL cells was only small in the majority of cases. As shown in Figure 3 , the median change in accumulated DNR content after 60 min of uptake was +2.5% for 2 M PSC 833 (range −5% to +24%; n = 42), +2% for 4 M CsA (range −9% to +22%; n = 25), +11.5% for 6 M Vp (range −17% to +95%; n = 14) and −2.5% for 25 M genistein (range −10% to +10%; n = 10) compared with the accumulated DNR content in the absence of modulators. The median change in retained DNR content measured after 60 min of efflux was nil; PSC 833 −1% (range −3% to +4%; n = 35), CsA 0% (range −3% to +3%; n = 23), Vp 0% (range −2% to +2%; n = 13) and genistein 0% (range −4% to +3%; n = 10). Comparable results were obtained when the accumulation and retention were measured after 300 min of incubation (steady state in the Relationship between DNR cytotoxicity and the modulating effect of 2 M PSC 833 (a), 4 M CsA (b), 6 M Vp (c) and 25 M genistein (d). Samples are ranked on the x-axis according to the in vitro DNR cytotoxicity observed in the absence of the modulator (the most DNR resistant samples at right). The modulating effect represents the ratio between the cytotoxicity of DNR in the presence and absence of the modulator and has been categorized into a sensitizing or an adverse effect, ie becoming respectively more sensitive or more resistant to DNR. For PSC 833, CsA and Vp the same patient samples were used, which are ranked equally in a-c. For genistein, partly different samples were used, which resulted in a different ranking of the patient samples compared with a-c. intracellular DNR content), or when cells were incubated with a lower DNR concentration of 1 g/ml DNR.
The effect of PSC 833, CsA, Vp and genistein on the accumulated and retained DNR content did not correspond with the modulating effect on the cytotoxicity of DNR (R s : P Ͼ 0.05 for each modulator) nor with the expression of P-gp, MRP and LRP (R s : P Ͼ 0.05 for each combination of modulator and drug resistance protein). Discrepancies between the modulating effect on DNR cytotoxicity, DNR accumulation/retention and expression of drug resistance proteins were often observed. Figure 4 illustrates the discrepancies between the expression of P-gp, MRP and LRP and the effect of modulators on the accumulated DNR content in three patients: patient 1 is clearly P-gp and MRP positive but neither the accumulation nor the cytotoxicity of DNR was modulated by PSC 833, CsA or Vp whereas genistein made the patient in vitro 2.3-fold more resistant to DNR; patient 2 is only clearly positive for MRP, no effect of PSC 833 on the accumu- The median percentage of change in the intracellular DNR content in the presence of the modulator compared to the control situation in the absence of the modulator (contr) is depicted by squares, the range is depicted by diamonds. Accumulation, measured after 60 min of uptake: PSC, n = 42; CsA, n = 25; Vp, n = 14; GS, n = 10. Retention, measured after 60 min of efflux: PSC, n = 35; CsA, n = 23; Vp, n = 13; GS, n = 10. lation of DNR was observed whereas this modulator made cells 3.5-fold more resistant to DNR; patient 3 clearly expressed all three drug resistance proteins, PSC 833 and Vp but not CsA and genistein had a small effect on the accumulated DNR content (respectively +17% and +12%) whereas the sensitizing effect on DNR cytotoxicity was most pronounced in the presence of CsA (1.5-fold).
Discussion
In vitro testing of the effect of modulators on the cytotoxicity of drugs may be useful to screen for potentially clinically applicable modulators as well as to study the underlying mechanism of modulation. In the present study, the effect of modulators on the in vitro cytotoxic response to DNR was measured by the well-characterized MTT assay. [13] [14] [15] [16] The modulators were tested at concentrations which resulted in less than 15% cell kill when incubated for 4 days, ie 2 M PSC 833, 4 M CsA, 6 M Vp and 25 M genistein. Phase I/II trials showed that these concentrations are also clinically achievable for PSC 833, CsA and Vp (unknown for genistein). 21 In the present study, PSC 833, CsA and Vp significantly sensitized the majority of childhood ALL samples, however, genistein made samples more resistant to DNR. Because genistein itself was rather cytotoxic when tested at 25 M (15% cell kill) we also studied the effect of a less toxic concentration of 5 M (Ͻ5% cell kill). This lower concentration also had an adverse effect on the in vitro response to DNR. Remarkably, the adverse effect was significantly higher in DNR-sensitive compared with DNR-resistant samples. The adverse effect of genistein could not be explained by an increased mitochondrial activity resulting in a higher formazan production as reported by Pagliacci et al, 22 because the optical density expressed per viable cell did not differ between cells cultured with and without genistein. Therefore, the present data suggest that genistein is unsuitable for modulation of DNR resistance in childhood ALL.
The overall sensitizing effect of PSC 833, CsA and Vp on DNR cytotoxicity was small (median between 1.2-and 1.6-fold under the present experimental conditions), but even a small modulating effect may be of clinical benefit in the treatment of leukemia. However, the extent of modulating the DNR cytotoxicity was not related to the degree of DNR resistance. Moreover, the effect of each modulator on the cytotox-icity of DNR did not differ between initial and relapse childhood ALL samples although the latter were more resistant to DNR as observed in this and in previous studies. 23, 24 In a few samples the modulators PSC 833, CsA and Vp even had an adverse effect on DNR cytotoxicity. This warns against the general use of PSC 833, CsA and Vp in childhood ALL, and implies that the therapeutic benefit of the modulator should be determined in each patient prior to its use. Samples in which an adverse effect of a modulator on DNR cytotoxicity is observed, may have benefit from the use of a different modulator, eg two patient samples with an adverse effect of PSC 833 of 3.5-and Ͼ1.9-fold became more sensitive to DNR in the presence of CsA and Vp (Figure 1, a-c) . Caution should be taken in the use of CsA, because an increase was observed in the cell survival of seven samples compared with the survival of cells cultured without CsA. The stimulation of cell survival by CsA has been demonstrated before 23, 25 and suggests that CsA should preferably not be used as a modifying agent in childhood ALL.
Sensitization to drugs by modulators including PSC 833, CsA and Vp has often been observed in adult acute leukemia, especially in adult acute myeloid leukemia (AML). [26] [27] [28] [29] These modulators also markedly increased the accumulation and retention of DNR or the marker agents rhodamine 123 and DiOC 2 . [28] [29] [30] [31] [32] In adult AML, the sensitizing effect on drug resistance and the increase in drug accumulation and retention was often correlated with the expression of P-gp. [32] [33] [34] However, discordant cases have also been reported, ie samples that were Pgp positive without detectable modulation of drug resistance, accumulation or retention and vice versa. 28, 33, 35, 36 These data suggest either a technical shortcoming or that other mechanisms of drug resistance may be present in these patients such as alterations in activity and/or quantity of DNA topoisomerase II, glutathione, glutathione S-transferases, MRP and LRP, an altered intracellular drug distribution or inhibition of apoptosis. 37 Inconsistent data about the contribution of P-gp to drug resistance and treatment outcome have also been reported in childhood acute leukemia. 23, [38] [39] [40] [41] [42] We recently showed that expression of P-gp and MRP did not correlate with the intracellular DNR concentration and in vitro resistance to DNR in a large series of childhood ALL samples. 17, 43 In contrast, the expression of LRP inversely correlated with the in vitro cytotoxicity and intracellular concentration of DNR. The function of the vault protein LRP is unknown yet, but the co-localization of vaults/LRP with the nuclear membrane and vesicles implies a role in the intracellular transport of molecules. 44, 45 In the present study, the changes in the accumulation and retention of DNR in the presence of modulators were small in most leukemic samples whereas a clear increase in DNR accumulation and retention was observed in DNR-resistant KB8-5 cells. No relationship was observed between the effect of modulators on the cytotoxicity, accumulation and retention of DNR and the expression of P-gp, MRP or LRP in childhood ALL. This suggests that either our method was not sufficiently sensitive to demonstrate a relationship in childhood ALL cells or that the sensitizing effect of PSC 833, CsA and Vp on the in vitro response to DNR may be related to modulation of other cellular targets, as has also been suggested by others. 28 In this respect, Vp has been reported to alter the intracellular solubility of DNR which may influence the bio-availability and intracellular distribution of the drug. 46 In cell lines, Vp changed the intracellular distribution of DNR and doxorubicin resulting in an increased nuclear/cytoplasmic ratio of these drugs. 9, 47, 48 The modulators may also lower the intracellular pH which may enhance the protonation and cytotoxicity of DNR. 49 More detailed studies are necessary to establish the nature of the sensitizing effect on DNR cytotoxicity in childhood ALL.
In vitro modulation of DNR cytotoxicity focuses only on the cellular response to the reversing agent. Besides the cellular response, the clinical use of modulators depends on the pharmacokinetics and side-effects of the agent. Phase I studies showed that both CsA and PSC 833 increased the area under the curves of etoposide, daunorubicin and doxorubicin. [50] [51] [52] [53] [54] However, a disadvantage of this increase in plasma levels is that drug doses should be reduced to limit the toxic sideeffects. Side-effects have been reported at the clinically achievable concentrations of PSC 833, CsA and Vp used in the present study. These were shown to be severe for Vp, including hypotension and cardiac failure. 55 The toxicity of CsA was milder, mainly resulting in myelosuppression and hypomagnesemia. 52, 56, 57 The lowest toxicities were reported for PSC 833 and included ataxia and intestinal neuropathy.
In conclusion, PSC 833, CsA and Vp but not genistein may be clinically applicable modulating agents in childhood ALL. The data on side-effects and the increase of cell survival by CsA might suggest that PSC 833 is more preferred than CsA and Vp in childhood ALL. The adverse effect on DNR cytotoxicity incidentally found using PSC 833, CsA and Vp warns against the general application of modulators in childhood ALL. The in vitro cellular response to the modulator and DNR may be used to select patients who may benefit from the modulator and not only suffer from its adverse-and sideeffects. The mechanism by which cells are sensitized to DNR remains unknown but the present data do not support the hypothesis that an increase of the intracellular DNR content and/or interaction with P-gp, MRP or LRP contribute to the sensitizing effect on the cytotoxicity of DNR in childhood ALL.
